ESMO 2026: NEOASIS Study Evaluates Neoadjuvant Botensilimab Plus Balstilimab in dMMR Colorectal Cancer At ESMO Congress 2026, Emma van den Berg presented results from the Phase II NEOASIS study (837P), evaluating short-course neoadjuvant botensilimab plus balstilimab in 18 patients with non-metastatic, resectable dMMR colorectal cancer. Key findings: ▫️ Major pathological response (MPR): 83% (15/18), meeting the prespecified primary endpoint. ▫️ Pathological complete response (pCR): 72% (13/18). ▫️ Safety: Grade 1–2 immune-related adverse events occurred in 72% of patients. One Grade 3 colitis event and two cases of ileus were reported. ▫️ Organ preservation: One patient with synchronous colon and rectal tumours opted for rectal organ preservation following a complete endoscopic response, while undergoing surgery for the colon tumour. Takeaway: Short-course neoadjuvant botensilimab plus balstilimab showed high rates of pathological response in this small Phase II dMMR colorectal cancer cohort. The findings support further investigation, including an ongoing rectal cancer organ-preservation cohort. @MyriamChalabi @Agenus_Bio @oncodaily @myESMO oncodaily.com/gastrointestin… #ESMO26 #ESMO2026 #OncoDaily #ColorectalCancer #NEOASIS #Immunotherapy